DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered. In addition to forecasting incident and prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy in the United States, Europe, and Japan.
DRG Epidemiology’s epilepsy forecast will answer the following questions:
Of all people with epilepsy, how many in the countries have been formally diagnosed?
Of all people diagnosed with epilepsy, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of epilepsy over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following epilepsy subpopulations:
Diagnosed prevalence of Lennox-Gastaut cases by intractable epilepsy.
Diagnosed prevalent cases by risk of acute repetitive seizures.
Diagnosed prevalent cases by drug-treatment status.
Diagnosed prevalent cases by seizure level.
Diagnosed prevalence ofLennox-Gastaut cases by type of seizure.
Diagnosed prevalence of Lennox-Gastaut cases by status epilepticus.
Drug-treated prevalent cases by drug-resistance status.
Prevalence of Epilepsy per 1,000 People of All Ages in 2021 and 2041ttttttttttttttt
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Epilepsy Over the Next 20 Yearstttttttttttttttt
Analysis of Diagnosed Prevalent Cases of Epilepsy in the Countries Under Study in 2021 by Type of Seizurettttttttttttttt
Epidemiology Data
Methods
Diagnosed Prevalent Cases
Type of Epileptic Seizure
Drug-Resistant Epilepsy
Acute Repetitive Seizures
Percentage Drug-Treated
Diagnosed Prevalence of Dravet Syndrome
Diagnosed Incidence of Dravet Syndrome
Dravet Syndrome With Status Epilepticus
Dravet Syndrome With the SCN1A Mutation
Reference Materials
Literature Review
Studies Included in the Analysis of Epilepsy
Studies Excluded From the Analysis of Epilepsy
Risk/Protective Factors
Bibliography
Abbreviation
Glossary
Shilpa Thakur
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.
